TROP-2 ADC in TNBC and HR+/HER2– Breast Cancer
Sector
Biotech
Company
Emerging Biopharma
Therapeutic Area
Oncology
Treatment Modality
Antibody-Drug Conjugate
Product Stage
Clinical
Expertise
Strategy
As an emerging biotech expanded its Phase 1a/b program of a TROP-2 ADC to include triple-negative and HR+/HER2– breast cancer, the communications challenge intensified. While preliminary efficacy data showed promise in both cohorts, the field demanded clarity on differentiation from approved TROP-2 therapies and other late-line competitors.
Situation
As an emerging biotech expanded its Phase 1a/b program of a TROP-2 ADC to include triple-negative and HR+/HER2– breast cancer, the communications challenge intensified. While preliminary efficacy data showed promise in both cohorts, the field demanded clarity on differentiation from approved TROP-2 therapies and other late-line competitors.
Situation
Approach
We built a cross-indication narrative that explained the rationale for cohort expansion and contextualized efficacy and safety data across tumor types. Abstracts, posters, and congress presentations highlighted consistency of activity while acknowledging limitations of early-stage studies. Advisory boards with oncology KOLs were used to refine messaging and stress-test trial positioning.
We built a cross-indication narrative that explained the rationale for cohort expansion and contextualized efficacy and safety data across tumor types. Abstracts, posters, and congress presentations highlighted consistency of activity while acknowledging limitations of early-stage studies. Advisory boards with oncology KOLs were used to refine messaging and stress-test trial positioning.
Approach
Results
Through coordinated publications and congress presence, the company reinforced the scientific relevance of its program in both TNBC and HR+/HER2–. By positioning expansion data transparently, the program built confidence among KOLs while setting expectations for progression into later-phase trials.
Through coordinated publications and congress presence, the company reinforced the scientific relevance of its program in both TNBC and HR+/HER2–. By positioning expansion data transparently, the program built confidence among KOLs while setting expectations for progression into later-phase trials.
Situation
As an emerging biotech expanded its Phase 1a/b program of a TROP-2 ADC to include triple-negative and HR+/HER2– breast cancer, the communications challenge intensified. While preliminary efficacy data showed promise in both cohorts, the field demanded clarity on differentiation from approved TROP-2 therapies and other late-line competitors.
Approach
We built a cross-indication narrative that explained the rationale for cohort expansion and contextualized efficacy and safety data across tumor types. Abstracts, posters, and congress presentations highlighted consistency of activity while acknowledging limitations of early-stage studies. Advisory boards with oncology KOLs were used to refine messaging and stress-test trial positioning.
Results
Through coordinated publications and congress presence, the company reinforced the scientific relevance of its program in both TNBC and HR+/HER2–. By positioning expansion data transparently, the program built confidence among KOLs while setting expectations for progression into later-phase trials.
*Impact studies reflect the collective experience of Biography and its partners.
Other Work
Work With Us
Advance biology to belief—
sharper, faster, and leaner.
Connect with our Biography team to explore AutoBio deployment.
Work With Us
Advance biology to belief—
sharper, faster, and leaner.
Connect with our Biography team to explore AutoBio deployment.
Work With Us
Advance biology to belief—sharper, faster, and leaner.
Connect with our Biography team to explore AutoBio deployment.